{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 35/80', 'must report this immediately, and under no circumstances later than 24 hours after being', 'made aware.', 'The safety of GLPG1690 during breastfeeding is unknown. Women who are nursing are not', 'allowed to take part in this clinical study.', '4.5.3.1.2.', 'Male subjects', 'Men should be advised not to father a child while receiving treatment and must use effective', 'contraception during and up to 90 days after treatment. Male subjects intending to father a', 'child, should discontinue treatment with IMP and wait for at least 90 days before stopping the', 'contraceptive measures detailed in this section.', 'Non-vasectomized male subjects with female partners of childbearing potential must be', 'willing to use a condom from the time of the first dose of IMP, during the clinical study, and', 'for at least 90 days after the last dose of IMP, in addition to having their female partner use', 'one of the following forms of contraception:', '-', 'Combined (estrogen and progesterone containing) (oral, intravaginal, transdermal)', 'hormonal contraception associated with inhibition of ovulation.', '-', 'Progesterone-only hormonal (oral, injectable, implantable) contraception associated', 'with inhibition of ovulation.', '-', 'Intrauterine device.', '-', 'Intrauterine hormone-releasing system.', 'Sexual abstinence defined as refraining from heterosexual intercourse during the entire period', 'of risk associated with the study treatments is considered a highly effective contraceptive', 'measure. The reliability of sexual abstinence needs to be evaluated in relation to the duration', 'of the clinical trial and the preferred and usual lifestyle of the subject.', 'Periodic abstinence (e.g. calendar, symptothermal, post-ovulation methods), declaration of', 'abstinence for the duration of a clinical study, withdrawal, spermicides only, and lactational', 'amenorrhea method are not acceptable methods of contraception.', 'In a case where the female partner of a male participant has undergone documented surgical', 'sterilization that was performed more than 1 year before screening, then the subject is not', 'required to use an additional form of contraception.', 'Vasectomized male subjects with female partners of childbearing potential are not required to', 'use an additional form of contraception providing that surgical sterilization has been', 'successful (documented azoospermia by semen analysis).', 'No sperm donation is allowed from first dose of IMP, during the clinical study, and until', '90 days after the last dose of IMP.', '4.5.3.2.', 'Prior and Concomitant Medications', 'Prior Medication', 'Prior medication taken up to 12 weeks prior to and during the screening period will be recorded', 'after signing of the ICF, at Visit 1.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 36/80', 'Concomitant Medication', 'Should any treatment other than the IMP be used during the course of the study, the name of', 'the medication, the dosage, the route, the reason for medication, and the start and stop dates of', 'administration must be recorded in the CRF until Follow-up Visit 2.', 'Concomitant medications taken for the long-term treatment of pre-existing conditions can', 'continue during the study, provided they are in accordance with the in- and exclusion criteria', '(see Sections 4.5.1 and 4.5.2, respectively). It is required that these medications are stabilized', 'prior to study entry (8 weeks prior to screening, or longer if t1/2 and/or time to reach steady state', 'of the drug requires) and preferably continue without variation of dose or regimen during the', 'study.', 'In case additional concomitant medication needs to be administered or dose adjustments for', 'pre-existing conditions need to be performed during the study, the benefit-risk to the subject', 'should be carefully assessed and consideration given to the timing of any necessary introduction', 'of new medications.', 'The following medications are prohibited within 4 weeks prior to the baseline visit and during', 'the treatment period: warfarin, antifibrotic agents (including colchicine, minocycline, tyrosine', 'kinase inhibitors [nilotinib, imatinib, dasatinib, nintedanib], pirfenidone), bosentan or Type 1', 'oral collagen. The following medications are prohibited within 3 months prior to the baseline', 'visit and during the treatment period: steady dose of prednisone or its equivalent >10 mg/day,', 'methotrexate >20 mg/week, azathioprine >150 mg/day, MMF >3 g/day, mycophenolic acid', '>2.16 g/day, leflunamide >20 mg/day. Cyclophosphamide is prohibited within 6 months prior', 'to the baseline visit and during the treatment period, as well as the following biologics:', 'tocilizumab or other drugs targeting IL-6/IL-6 receptor, abatacept, anti-tumor necrosis factor', '(TNF) drugs, rituximab, belimumab, or other monoclonal antibodies.', \"If during the study, the subject's condition necessitates the use of one of the abovementioned\", 'medications (excluding prednisone or its equivalent >10 mg/day), the use of IMP should be', 'interrupted until resolution or stabilization of this condition, preferably after consultation with', 'the contract research organization (CRO) medical monitor (as per study contact list) or', \"sponsor's study physician (if the former is not available).\", 'Precautions with concomitant medication known to prolong the QT interval', 'The use of medication known to prolong QT interval during the study needs to be based on a', 'benefit-risk evaluation by the investigator, e.g. in the case of atrial fibrillation. In certain other', 'situations (e.g. the initiation of macrolides or fluoroquinolones in case of a lower respiratory', 'tract infection), when the benefit-risk evaluation necessitates the administration of medication', 'known to or potentially prolonging QT, IMP can be interrupted as evaluated by the investigator', \"after clinical assessment of the subject's profile, including the baseline QTcF and how this has\", 'changed over time for this specific subject. If the investigator elects to continue IMP, additional', \"monitoring will be performed as per investigator's judgment. A nonexhaustive list of\", 'medication known to prolong QT interval is provided in Appendix 5. Note: In case QT interval', 'prolongation is reported in a subject while receiving one of these medications, the investigator', 'should follow the labels and Risk Evaluation and Mitigation Strategies guidance.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}